WXS was performed on normal-tumour sample pairs collected from twenty-two patients with HER2+ early stage breast cancer who had received neoadjuvant anti-HER2 targeted therapy in combination with chemotherapy as part of the TCHL phase II clinical trial (ICORG10–05/NCT01485926) (Fig. 1a). This evidence concerns the gene ERBB2 and neoplasm.